Kobexindo Spread Rp 11.4 Billion Dividend to Shareholders

Kobexindo Tractors Tbk PT (KOBX) plans to distribute dividends of U.S. $ 1.2 million or equivalent to Rp 11.4 billion. This dividend equal 23% of the company’s net profit in 2012.

Each shareholder will receive dividends KOBX Rp 5 per share. The Company will put about 77% or U.S. $ 3.99 million of net income as retained earnings and general reserves.

The funding will be used to strengthen the Company’s capital structure, especially in business development and financing of the Company’s operations and its subsidiary entities.

“The decision has considered the need for capital to fund the Company’s business and operational expansion.” Explained Director of Public Relations Kobexindo Soputro in a written statement on Wednesday (06/12/2013).

Throughout 2012, the Company posted revenue of U.S. $ 131 million. Revenue was driven by sales of heavy equipment, parts, and revenues from repair services.

Heavy equipment sales segment revenue in 2012 was U.S. $ 114 million dollars. This segment is the largest revenue contribution by donating 87% of the Company’s total revenues in 2012.

The second contributor to revenues derived from spare parts and service segment of U.

Impact of Selling Assets in 2011, Merck Profit Drops 53%

Pharmaceutical and chemical company, PT Merck Tbk recorded a decrease in net income in 2012. The German issuers, incised profit of Rp 108 billion, down 53.24% from the previous period which amounted to Rp 231.16 billion.

Director of Finance Bambang Nurcahyo explain, the decline in 2012 net profit, due in 2011, the company is selling assets. This has an impact on revenues soaring Merck in 2011, while in 2012, there is no asset sales.

“The decline in performace 2012, causes the 2011 to sell property assets and Kemang BSD net profit of Rp 70 billion. Assets sold in 2011,” said Bambang at Public Expose Merck headquarters in Pasar Rebo, East Jakarta, Wednesday (20/03/2013).

In 2012, Merck’s sales reached Rp 930 billion, up 1.18% from the 2012 period amounted to Rp 919 billion. This sale, supported by three business units namely Chemicals Rp 359 billion, Merck Serono worth Rp 405 billion and Rp Consumer Healthcare 166 billion.

Merck also will perform a dividend of Rp 75 billion to shareholders. However, Bambang reluctant to mention the target profit, revenue and business plans and capital expenditures in 2013.